Psoriatic arthritis.
Journal
Nature reviews. Disease primers
ISSN: 2056-676X
Titre abrégé: Nat Rev Dis Primers
Pays: England
ID NLM: 101672103
Informations de publication
Date de publication:
12 08 2021
12 08 2021
Historique:
accepted:
07
07
2021
entrez:
13
8
2021
pubmed:
14
8
2021
medline:
26
11
2021
Statut:
epublish
Résumé
Psoriatic arthritis (PsA) is a complex inflammatory disease with heterogeneous clinical features, which complicates psoriasis in 30% of patients. There are no diagnostic criteria or tests available. Diagnosis is most commonly made by identifying inflammatory musculoskeletal features in joints, entheses or the spine in the presence of skin and/or nail psoriasis and in the usual absence of rheumatoid factor and anti-cyclic citrullinated peptide. The evolution of psoriasis to PsA may occur in stages, although the mechanisms are unclear. In many patients, there may be little or no relationship between severity of musculoskeletal inflammation and severity of skin or nail psoriasis. The reason for this disease heterogeneity may be explained by differences in genotype, especially in the HLA region. New targeted therapies for PsA have been approved with additional therapies in development. These developments have substantially improved both short-term and long-term outcomes including a reduction in musculoskeletal and skin manifestations and in radiographic damage. With efforts underway aimed at improving our understanding of the molecular basis for the heterogeneity of PsA, a personalized approach to treating PsA may become possible.
Identifiants
pubmed: 34385474
doi: 10.1038/s41572-021-00293-y
pii: 10.1038/s41572-021-00293-y
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
59Informations de copyright
© 2021. Springer Nature Limited.
Références
Ritchlin, C. T., Colbert, R. A. & Gladman, D. D. Psoriatic arthritis. N. Engl. J. Med. 376, 2095–2096 (2017). A comprehensive review of psoriatic arthritis.
pubmed: 28538114
doi: 10.1056/NEJMra1505557
Winchester, R. & FitzGerald, O. The many faces of psoriatic arthritis: their genetic determinism. Rheumatology 59, i4–i9 (2020).
pubmed: 32159794
pmcid: 7065456
doi: 10.1093/rheumatology/kez325
Haroon, M., Kirby, B. & FitzGerald, O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann. Rheum. Dis. 72, 736–740 (2013). This paper demonstrates the large number of patients with psoriatic arthritis attending dermatology clinics.
pubmed: 22730367
doi: 10.1136/annrheumdis-2012-201706
Bowes, J. et al. Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. Ann. Rheum. Dis. 70, 1641–1644 (2011).
pubmed: 21623003
doi: 10.1136/ard.2011.150102
Hüffmeier, U. et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis. Nat. Genet. 42, 996–999 (2010).
pubmed: 20953186
pmcid: 2981079
doi: 10.1038/ng.688
Menon, B. et al. Interleukin-17
pubmed: 24470327
pmcid: 4158887
doi: 10.1002/art.38376
Alinaghi, F. et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J. Am. Acad. Dermatol. 80, 251–265 (2019).
pubmed: 29928910
doi: 10.1016/j.jaad.2018.06.027
Scotti, L., Franchi, M., Marchesoni, A. & Corrao, G. Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis. Semin. Arthritis Rheum. 48, 28–34 (2018).
pubmed: 29398124
doi: 10.1016/j.semarthrit.2018.01.003
Ogdie, A. et al. Prevalence and treatment patterns of psoriatic arthritis in the UK. Rheumatology 52, 568–575 (2013).
pubmed: 23221331
doi: 10.1093/rheumatology/kes324
Kaufman, B. P. & Alexis, A. F. Psoriasis in skin of color: Insights into the epidemiology, clinical presentation, genetics, quality-of-life impact, and treatment of psoriasis in non-white racial/ethnic groups. Am. J. Clin. Dermatol 19, 405–423 (2018).
pubmed: 29209945
doi: 10.1007/s40257-017-0332-7
Weiss, P. F. & Roth, J. Juvenile- versus adult-onset spondyloarthritis: similar, but different. Rheum. Dis. Clin. North. Am. 46, 241–257 (2020).
pubmed: 32340699
doi: 10.1016/j.rdc.2020.01.003
Petty, R. E. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 31, 390–392 (2004).
pubmed: 14760812
Stoll, M. L., Lio, P., Sundel, R. P. & Nigrovic, P. Comparison of Vancouver and International League of Associations for Rheumatology classification criteria for juvenile psoriatic arthritis. Arthritis Rheum. 59, 51–58 (2008).
pubmed: 18163407
doi: 10.1002/art.23240
Southwood, T. R. et al. Psoriatic arthritis in children. Arthritis Rheum. 8, 1007–1013 (1989).
doi: 10.1002/anr.1780320810
Brandon, T. G., Manos, C. K., Xiao, R., Ogdie, A. & Weiss, P. F. Pediatric psoriatic arthritis: a population-based cohort study of risk factors for onset and subsequent risk of inflammatory comorbidities. J. Psoriasis Psoriatic Arthritis 3, 131–136 (2018).
pubmed: 31355354
pmcid: 6660180
doi: 10.1177/2475530318799072
Ringold, S. et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Rheumatol. 71, 846–863 (2019).
pubmed: 31021537
pmcid: 6561114
doi: 10.1002/art.40884
Karmacharya, P., Chakradhar, R. & Ogdie, A. The epidemiology of psoriatic arthritis: a literature review. Best. Pract. Res Clin. Rheumatol. 75, 101692 (2021).
doi: 10.1016/j.berh.2021.101692
O’Rielly, D. D., Jani, M., Rahman, P. & Elder, J. The genetics of psoriasis and psoriatic arthritis. J. Rheumatol. Suppl. 95, 46–50 (2019).
pubmed: 31154404
doi: 10.3899/jrheum.190119
Scher, J. U., Ogdie, A., Merola, J. F. & Ritchlin, C. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat. Rev. Rheumatol. 15, 153–166 (2019). This review is state of the art in assessing early psoriatic arthritis, risk factors and strategies for future disease prevention.
pubmed: 30742092
doi: 10.1038/s41584-019-0175-0
Taylor, W. et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 54, 2665–2673 (2006). An important description of the CASPAR classification criteria.
pubmed: 16871531
doi: 10.1002/art.21972
Villani, A. P. et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J. Am. Acad. Dermatol. 73, 242–248 (2015).
pubmed: 26054432
doi: 10.1016/j.jaad.2015.05.001
Ogdie, A. The preclinical phase of PsA: a challenge for the epidemiologist. Ann. Rheum. Dis. 76, 1481–1483 (2017).
pubmed: 28274910
doi: 10.1136/annrheumdis-2017-211109
Gupta, S., Syrimi, Z., Hughes, D. M. & Zhao, S. S. Comorbidities in psoriatic arthritis: a systematic review and meta-analysis. Rheumatol. Int. 41, 275–284 (2021).
pubmed: 33423070
pmcid: 7835184
doi: 10.1007/s00296-020-04775-2
Kumthekar, A. & Ogdie, A. Obesity and psoriatic arthritis: a narrative review. Rheumatol. Ther. 7, 447–456 (2020).
pubmed: 32495313
pmcid: 7410935
doi: 10.1007/s40744-020-00215-6
Karmacharya, P., Ogdie, A. & Eder, L. Psoriatic arthritis and the association with cardiometabolic disease: a narrative review. Ther. Adv. Musculoskelet. Dis. 13, 1759720X21998279 (2021).
pubmed: 33737966
pmcid: 7934027
doi: 10.1177/1759720X21998279
Ogdie, A. & Weiss, P. The epidemiology of psoriatic arthritis. Rheum. Dis. Clin. North Am. 41, 545–568 (2015).
pubmed: 26476218
pmcid: 4610151
doi: 10.1016/j.rdc.2015.07.001
Dubreuil, M. et al. Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. Rheumatology 53, 346–352 (2014).
pubmed: 24185762
doi: 10.1093/rheumatology/ket343
Ogdie, A. et al. Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population-based study. Physiol. Behav. 176, 139–148 (2019).
Lukmanji, A., Basmadjian, R. B., Vallerand, I. A., Patten, S. B. & Tang, K. Risk of depression in patients with psoriatic disease: a systematic review and meta-analysis. J. Cutan. Med. Surg. 25, 257–270 (2020).
pubmed: 33263264
doi: 10.1177/1203475420977477
Mease, P. J. Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment. Curr. Opin. Rheumatol. 29, 304–310 (2017).
pubmed: 28394827
doi: 10.1097/BOR.0000000000000388
Lubrano, E., Scriffignano, S., Morelli, R. & Perrotta, F. Assessment of widespread and extra-articular pain in psoriatic arthritis: a case-control study. J. Rheumatol. https://doi.org/10.3899/jrheum.201163 (2021).
doi: 10.3899/jrheum.201163
pubmed: 33452167
Michelsen, B. et al. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. Ann. Rheum. Dis. 76, 1906–1910 (2017).
pubmed: 28733473
doi: 10.1136/annrheumdis-2017-211284
Elsawy, N. A., Helal, A. H., Abd ElHamid, H. A. & Yousra Hisham, A.-F. Fibromyalgia in patients with psoriatic arthritis: impact on disease activity indices, fatigue and health-related quality of life. Int. J. Rheum. Dis. 24, 189–196 (2021).
pubmed: 33073935
doi: 10.1111/1756-185X.13987
Bengtsson, K. et al. Incidence of extra-articular manifestations in ankylosing spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis: results from a national register-based cohort study. Rheumatology 60, 2725–2734 (2021).
pubmed: 33216939
doi: 10.1093/rheumatology/keaa692
Bradley, P. et al. Prevalence of extra-articular manifestations in psoriatic arthritis: a systematic review and meta-analysis. Rheumatology 59, 2199–2206 (2020).
doi: 10.1093/rheumatology/keaa062
O’Rielly, D. D. & Rahman, P. Genetic, epigenetic and pharmacogenetic aspects of psoriasis and psoriatic arthritis. Rheum. Dis. Clin. North Am. 41, 623–642 (2015).
pubmed: 26476223
doi: 10.1016/j.rdc.2015.07.002
Li, Q. et al. Quantifying differences in heritability among psoriatic arthritis (PsA), cutaneous psoriasis (PsC) and psoriasis vulgaris (PsV). Sci. Rep. 10, 4925 (2020).
pubmed: 32188927
pmcid: 7080781
doi: 10.1038/s41598-020-61981-5
Winchester, R. et al. HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. Arthritis Rheum. 64, 1134–1144 (2012). An important study of the HLA genetic associations in patients with psoriatic arthritis in comparison to those with psoriasis only.
pubmed: 22006066
doi: 10.1002/art.33415
Okada, Y. et al. Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes. Am. J. Hum. Genet. 95, 162–172 (2014).
pubmed: 25087609
pmcid: 4129407
doi: 10.1016/j.ajhg.2014.07.002
Bowes, J. et al. Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis. Ann. Rheum. Dis. 76, 1774–1779 (2017).
pubmed: 28821532
doi: 10.1136/annrheumdis-2017-211414
Winchester, R. & Fitzgerald, O. MHC class I associations beyond HLA-B27: the peptide binding hypothesis of psoriatic arthritis and its implications for disease pathogenesis. Curr. Opin. Rheumatol. 32, 330–336 (2020).
pubmed: 32412996
doi: 10.1097/BOR.0000000000000720
Haroon, M., Winchester, R., Giles, J. T., Heffernan, E. & FitzGerald, O. Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. Ann. Rheum. Dis. 75, 155–162 (2016).
pubmed: 25261574
doi: 10.1136/annrheumdis-2014-205461
Bowes, J. et al. Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. Nat. Commun. 6, 7741 (2015).
pubmed: 26145464
pmcid: 5784513
doi: 10.1038/ncomms8741
Apel, M. et al. Variants in RUNX3 contribute to susceptibility to psoriatic arthritis, exhibiting further common ground with ankylosing spondylitis. Arthritis Rheum. 65, 1224–1231 (2013).
pubmed: 23401011
doi: 10.1002/art.37885
Green, A. et al. Modifiable risk factors and the development of psoriatic arthritis in people with psoriasis. Br. J. Dermatol. 182, 714–720 (2020). An important sudy of modifiable risk factors for the development of psoriatic arthritis in patients with psoriasis.
pubmed: 31209855
doi: 10.1111/bjd.18227
Thorarensen, S. M. et al. Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis. Ann. Rheum. Dis. 76, 521–525 (2017).
pubmed: 27457510
doi: 10.1136/annrheumdis-2016-209334
Schett, G. et al. Enthesitis: from pathophysiology to treatment. Nat. Rev. Rheumatol. 13, 731–741 (2017).
pubmed: 29158573
doi: 10.1038/nrrheum.2017.188
Teng, Y. et al. Infection-provoked psoriasis: induced or aggravated (Review). Exp. Ther. Med. 21, 567 (2021).
pubmed: 33850539
pmcid: 8027725
doi: 10.3892/etm.2021.9999
FitzGerald, O., Haroon, M., Giles, J. T. & Winchester, R. Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res. Ther. 17, 115 (2015).
pubmed: 25948071
pmcid: 4422545
doi: 10.1186/s13075-015-0640-3
Gilis, E. et al. The role of the microbiome in gut and joint inflammation in psoriatic arthritis and spondyloarthritis. J. Rheumatol. Suppl. 94, 36–39 (2018).
pubmed: 29858352
doi: 10.3899/jrheum.180135
Abusleme, L. & Moutsopoulos, N. IL-17: overview and role in oral immunity and microbiome. Oral. Dis. 23, 854–865 (2017).
pubmed: 27763707
doi: 10.1111/odi.12598
Schluter, J. et al. The gut microbiota is associated with immune cell dynamics in humans. Nature 588, 303–307 (2020).
pubmed: 33239790
pmcid: 7725892
doi: 10.1038/s41586-020-2971-8
Jadon, D. R., Stober, C., Pennington, S. R. & FitzGerald, O. Applying precision medicine to unmet clinical needs in psoriatic disease. Nat. Rev. Rheumatol. 16, 609–627 (2020). This article discusses unmet clinical needs in psoriatic arthritis focusing on joint damage and treatment response prediction.
pubmed: 33024296
doi: 10.1038/s41584-020-00507-9
Queiro, R. et al. HLA-C locus alleles may modulate the clinical expression of psoriatic arthritis. Arthritis Res. Ther. 8, R185 (2006).
pubmed: 17166285
pmcid: 1794531
doi: 10.1186/ar2097
Leijten, E. F. et al. Tissue-resident memory CD8+ T cells from skin differentiate psoriatic arthritis from psoriasis. Arthritis Rheumatol. 73, 1220–1232 (2021).
pubmed: 33452865
doi: 10.1002/art.41652
Steel, K. J. A. et al. Polyfunctional, proinflammatory, tissue-resident memory phenotype and function of synovial interleukin-17A+CD8+ T cells in psoriatic arthritis. Arthritis Rheumatol. 72, 435–447 (2020).
pubmed: 31677365
pmcid: 7065207
doi: 10.1002/art.41156
Polachek, A. et al. The association between HLA genetic susceptibility markers and sonographic enthesitis in psoriatic arthritis. Arthritis Rheumatol. 70, 756–762 (2018); erratum 71, 625 (2019).
Costello, P. J. et al. Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. J. Immunol. 166, 2878–2886 (2001).
pubmed: 11160357
doi: 10.4049/jimmunol.166.4.2878
Cañete, J. D. et al. Ectopic lymphoid neogenesis in psoriatic arthritis. Ann. Rheum. Dis. 66, 720–726 (2007).
pubmed: 17223654
pmcid: 1954653
doi: 10.1136/ard.2006.062042
Penkava, F. et al. Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis. Nat. Commun. 11, 4767 (2020).
pubmed: 32958743
pmcid: 7505844
doi: 10.1038/s41467-020-18513-6
Abji, F., Pollock, R. A., Liang, K., Chandran, V. & Gladman, D. D. Brief report: CXCL10 is a possible biomarker for the development of psoriatic arthritis among patients with psoriasis. Arthritis Rheumatol. 68, 2911–2916 (2016).
pubmed: 27389865
doi: 10.1002/art.39800
Moll, J. M. H. & Wright, V. Psoriatic arthritis. Semin. Arthritis Rheum. 3, 55–78 (1973).
pubmed: 4581554
doi: 10.1016/0049-0172(73)90035-8
Holland, R. et al. Psoriatic arthritis is associated with diagnostic delay and worse outcome at three months when compared to rheumatoid arthritis: results from the UK National Audit for Inflammatory Arthritis [abstract FRI0514]. Ann. Rheum. Dis. 76, 685 (2017).
Tillett, W. et al. Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis. Ann. Rheum. Dis. 72, 1358–1361 (2013).
pubmed: 23291384
doi: 10.1136/annrheumdis-2012-202608
Haroon, M., Gallagher, P. & FitzGerald, O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann. Rheum. Dis. 74, 1045–1050 (2015).
pubmed: 24525911
doi: 10.1136/annrheumdis-2013-204858
Mease, P. J., Garg, A., Helliwell, P. S., Park, J. J. & Gladman, D. D. Development of criteria to distinguish inflammatory from noninflammatory arthritis, enthesitis, dactylitis, and spondylitis: a report from the GRAPPA 2013 Annual Meeting. J. Rheumatol. 41, 1249–1251 (2014).
pubmed: 24882864
doi: 10.3899/jrheum.140182
Eder, L. & Gladman, D. D. Psoriatic arthritis: phenotypic variance and nosology. Curr. Rheumatol. Rep. 15, 316 (2013).
pubmed: 23371481
doi: 10.1007/s11926-013-0316-4
Bonifati, C. et al. The diagnosis of early psoriatic arthritis in an outpatient dermatological centre for psoriasis. J. Eur. Acad. Dermatol. Venereol. 26, 627–633 (2012).
pubmed: 21645122
doi: 10.1111/j.1468-3083.2011.04138.x
Kane, D., Stafford, L., Bresnihan, B. & FitzGerald, O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology 42, 1460–1468 (2003).
pubmed: 14523223
doi: 10.1093/rheumatology/keg384
Moghaddassi, M., Shahram, F., Chams-Davatchi, C., Najafizadeh, S. R. & Davatchi, F. Different aspects of psoriasis: analysis of 150 Iranian patients. Arch. Iran. Med. 12, 279–283 (2009).
pubmed: 19400606
Coates, L. C. et al. Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum. 64, 3150–3155 (2012).
pubmed: 22576997
doi: 10.1002/art.34536
Niccoli, L. et al. Frequency of iridocyclitis in patients with early psoriatic arthritis: a prospective, follow up study. Int. J. Rheum. Dis. 15, 414–418 (2012).
pubmed: 22898222
doi: 10.1111/j.1756-185X.2012.01736.x
Reich, K., Kruger, K., Mossner, R. & Augustin, M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br. J. Dermatol. 160, 1040–1047 (2009).
pubmed: 19210498
doi: 10.1111/j.1365-2133.2008.09023.x
Gladman, D. D., Ziouzina, O., Thavaneswaran, A. & Chandran, V. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. J. Rheumatol. 40, 1357–1359 (2013).
pubmed: 23818708
doi: 10.3899/jrheum.130163
Torre Alonso, J. C. et al. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br. J. Rheumatol. 30, 245–250 (1991).
pubmed: 1863819
doi: 10.1093/rheumatology/30.4.245
Scarpa, R. et al. Early psoriatic arthritis: the clinical spectrum. J. Rheumatol. 35, 137–141 (2008).
pubmed: 18050372
Coates, L. C. et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet 386, 2589–2598 (2015).
doi: 10.1016/S0140-6736(15)00347-5
Chandran, V., Barrett, J., Schentag, C. T., Farewell, V. T. & Gladman, D. D. Axial psoriatic arthritis: update on a longterm prospective study. J. Rheumatol. 36, 2744–2750 (2009).
pubmed: 19884276
doi: 10.3899/jrheum.090412
Battistone, M. J., Manaster, B. J., Reda, D. J. & Clegg, D. O. The prevalence of sacroilitis in psoriatic arthritis: new perspectives from a large, multicenter cohort. A Department of Veterans Affairs Cooperative Study. Skelet. Radiol. 28, 196–201 (1999).
doi: 10.1007/s002560050500
Helliwell, P. S., Hickling, P. & Wright, V. Do the radiological changes of classic ankylosing spondylitis differ from the changes found in the spondylitis associated with inflammatory bowel disease, psoriasis, and reactive arthritis? Ann. Rheum. Dis. 57, 135–140 (1998).
pubmed: 9640127
pmcid: 1752543
doi: 10.1136/ard.57.3.135
Jadon, D. R. et al. Axial disease in psoriatic arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis. Ann. Rheum. Dis. 76, 701–707 (2017).
pubmed: 27913376
doi: 10.1136/annrheumdis-2016-209853
Gladman, D. D., Shuckett, R., Russell, M. L., Thorne, J. C. & Schachter, R. K. Psoriatic arthritis (PSA)–an analysis of 220 patients. Q. J. Med. 62, 127–141 (1987).
pubmed: 3659255
Congi, L. & Roussou, E. Clinical application of the CASPAR criteria for psoriatic arthritis compared to other existing criteria. Clin. Exp. Rheumatol. 28, 304–310 (2010).
pubmed: 20576225
Tillett, W. et al. The classification for psoriatic arthritis (CASPAR) criteria–a retrospective feasibility, sensitivity, and specificity study. J. Rheumatol. 39, 154–156 (2012).
pubmed: 22089469
doi: 10.3899/jrheum.110845
Chandran, V., Schentag, C. T. & Gladman, D. D. Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. Arthritis Rheum. 57, 1560–1563 (2007).
pubmed: 18050230
doi: 10.1002/art.23104
van den Berg, R., van Gaalen, F., van der Helm-van Mil, A., Huizinga, T. & van der Heijde, D. Performance of classification criteria for peripheral spondyloarthritis and psoriatic arthritis in the Leiden Early Arthritis cohort. Ann. Rheum. Dis. 71, 1366–1369 (2012).
pubmed: 22504563
doi: 10.1136/annrheumdis-2011-201081
Jones, S. M. et al. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br. J. Rheumatol. 33, 834–839 (1994).
pubmed: 8081668
doi: 10.1093/rheumatology/33.9.834
Marsal, S. et al. Clinical, radiographic and HLA associations as markers for different patterns of psoriatic arthritis. Rheumatol 38, 332–337 (1999).
doi: 10.1093/rheumatology/38.4.332
Chandran, V., Tolusso, D. C., Cook, R. J. & Gladman, D. D. Risk factors for axial inflammatory arthritis in patients with psoriatic arthritis. J. Rheumatol. 37, 809–815 (2010).
pubmed: 20231209
doi: 10.3899/jrheum.091059
Gladman, D. D. & Farewell, V. T. Progression in psoriatic arthritis: role of time varying clinical indicators. J. Rheumatol. 26, 2409–2413 (1999).
pubmed: 10555902
Brockbank, J. E., Stein, M., Schentag, C. T. & Gladman, D. D. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann. Rheum. Dis. 64, 188–190 (2005).
pubmed: 15271771
doi: 10.1136/ard.2003.018184
Wervers, K. et al. Influence of disease manifestations on health-related quality of life in early psoriatic arthritis. J. Rheumatol. 45, 1526–1531 (2018).
pubmed: 29961685
doi: 10.3899/jrheum.171406
Coates, L. C. et al. Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). Br. J. Dermatol. 168, 802–807 (2013).
pubmed: 23311587
doi: 10.1111/bjd.12190
Haroon, M., Kirby, B. & Fitzgerald, O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2012-201706 (2012).
doi: 10.1136/annrheumdis-2012-201706
pubmed: 22863576
Coates, L. C. et al. Assessment of two screening tools to identify psoriatic arthritis in patients with psoriasis. J. Eur. Acad. Dermatol. Venereol. 32, 1530–1534 (2018).
pubmed: 29578628
doi: 10.1111/jdv.14971
National Institute for Health and Care Excellence. Psoriasis: assessment and management. Clinical guideline 153 (NICE, 2012).
Eder, L. et al. The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study. Arthritis Rheumatol. 68, 915–923 (2016).
pubmed: 26555117
doi: 10.1002/art.39494
Orbai, A.-M. et al. Updating the psoriatic arthritis (PsA) core domain set: a report from the PsA workshop at OMERACT 2016. J. Rheumatol. 44, 1522–1528 (2017).
pubmed: 28148697
pmcid: 5538953
doi: 10.3899/jrheum.160904
Ogdie, A., Coates, L. C. & Mease, P. Measuring outcomes in psoriatic arthritis. Arthritis Care Res. 72 (Suppl. 1), 82–109 (2020).
doi: 10.1002/acr.24242
Mease, P. J. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res. 63 (Suppl. 1), 64–85 (2011).
doi: 10.1002/acr.20577
Mease, P. & van der, H. D. Joint damage in psoriatic arthritis: how is it assessed and can it be prevented? Int. J. Adv. Rheumatol. 4, 38–48 (2006).
Kivitz, A. J. et al. A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis. Semin. Arthritis Rheum. 37, 164–173 (2007).
pubmed: 17570469
doi: 10.1016/j.semarthrit.2007.03.004
Dean, B. J. et al. The risks and benefits of glucocorticoid treatment for tendinopathy: a systematic review of the effects of local glucocorticoid on tendon. Semin. Arthritis Rheum. 43, 570–576 (2014).
pubmed: 24074644
doi: 10.1016/j.semarthrit.2013.08.006
Ritchlin, C. T. et al. Treatment recommendations for psoriatic arthritis. Ann. Rheum. Dis. 68, 1387–1394 (2009).
pubmed: 18952643
doi: 10.1136/ard.2008.094946
Mease, P. J. Biologic therapy for psoriatic arthritis. Rheum. Dis. Clin. North Am. 41, 723–738 (2015).
pubmed: 26476229
doi: 10.1016/j.rdc.2015.07.010
Ceponis, A. & Kavanaugh, A. Use of methotrexate in patients with psoriatic arthritis. Clin. Exp. Rheumatol. 28 (Suppl. 1), 132–137 (2010).
Mease, P. J. Spondyloarthritis: is methotrexate effective in psoriatic arthritis? Nat. Rev. Rheumatol. 8, 251–252 (2012).
pubmed: 22549279
doi: 10.1038/nrrheum.2012.56
Kingsley, G. H. et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatol 51, 1368–1377 (2012).
doi: 10.1093/rheumatology/kes001
Mease, P. J. et al. Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial. Arthritis Rheumatol. 71, 1112–1124 (2019).
pubmed: 30747501
pmcid: 6618246
doi: 10.1002/art.40851
Clegg, D. O. et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 39, 2013–2020 (1996).
pubmed: 8961906
doi: 10.1002/art.1780391210
Kaltwasser, J. P. et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 50, 1939–1950 (2004).
pubmed: 15188371
doi: 10.1002/art.20253
Mease, P. J. & Armstrong, A. W. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs 74, 423–441 (2014).
pubmed: 24566842
pmcid: 3958815
doi: 10.1007/s40265-014-0191-y
Mease, P. J. et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356, 985–990 (2000). This is an early randomized trial of a biological agent in the treatment of psoriatic arthritis.
doi: 10.1016/S0140-6736(00)02530-7
Antoni, C. E. et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 52, 1227–1236 (2005).
pubmed: 15818699
doi: 10.1002/art.20967
Fénix-Caballero, S. et al. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. J. Clin. Pharm. Ther. 38, 286–293 (2013).
pubmed: 23590560
doi: 10.1111/jcpt.12045
McInnes, I. B. et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382, 780–789 (2013).
doi: 10.1016/S0140-6736(13)60594-2
Ritchlin, C. et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann. Rheum. Dis. 73, 990–999 (2014).
pubmed: 24482301
doi: 10.1136/annrheumdis-2013-204655
Deodhar, A. et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 71, 258–270 (2019).
pubmed: 30225992
doi: 10.1002/art.40728
Kavanaugh, A. et al. Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2). Ann. Rheum. Dis. 75, 1984–1988 (2016).
pubmed: 27098404
doi: 10.1136/annrheumdis-2015-209068
Baraliakos, X. et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann. Rheum. Dis. 80, 582–590 (2021).
doi: 10.1136/annrheumdis-2020-218808
Mease, P. J. et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann. Rheum. Dis. 79, 123–131 (2020). This is the first head-to-head trial of an anti-TNF therapy versus an anti-IL-17 inhibitor.
pubmed: 31563894
doi: 10.1136/annrheumdis-2019-215386
McInnes, I. B. et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. Lancet 395, 1496–1505 (2020).
pubmed: 32386593
doi: 10.1016/S0140-6736(20)30564-X
Mease, P. J. et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N. Engl. J. Med. 370, 2295–2306 (2014).
pubmed: 24918373
doi: 10.1056/NEJMoa1315231
Mease, P. J. et al. Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. Ann. Rheum. Dis. 80, 185–193 (2021).
pubmed: 33106286
doi: 10.1136/annrheumdis-2019-216835
Ritchlin, C. T. et al. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet 395, 427–440 (2020).
pubmed: 32035552
doi: 10.1016/S0140-6736(19)33161-7
Bachelez, H. Interleukin 23 inhibitors for psoriasis: not just another number. Lancet 390, 208–210 (2017).
pubmed: 28596042
doi: 10.1016/S0140-6736(17)31474-5
Deodhar, A. et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 395, 1115–1125 2020).
pubmed: 32178765
doi: 10.1016/S0140-6736(20)30265-8
Mease, P. J. et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 395, 1126–1136 (2020).
pubmed: 32178766
doi: 10.1016/S0140-6736(20)30263-4
McInnes, I. B. et al. Efficacy and safety of guselkumab, an interleukin-23p19-specific monoclonal antibody, through one year in biologic-naive patients with psoriatic arthritis. Arthritis Rheumatol. 73, 604–616 (2021).
pubmed: 33043600
doi: 10.1002/art.41553
Mease, P. Ustekinumab fails to show efficacy in a phase III axial spondyloarthritis program: the importance of negative results. Arthritis Rheumatol. 71, 179–181 (2019).
pubmed: 30600936
doi: 10.1002/art.40759
Mease, P. Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial. Ann. Rheum. Dis. 77, 200–201 (2018).
Mease, P. J. et al. Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study. Ann. Rheum Dis. https://doi.org/10.1136/annrheumdis-2020-219014 (2021).
doi: 10.1136/annrheumdis-2020-219014
pubmed: 33985942
Mease, P. J. et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann. Rheum. Dis. 76, 1550–1558 (2017).
pubmed: 28473423
doi: 10.1136/annrheumdis-2016-210724
Kavanaugh, A. et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann. Rheum. Dis. 73, 1020–1026 (2014).
pubmed: 24595547
doi: 10.1136/annrheumdis-2013-205056
Cutolo, M. et al. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J. Rheumatol. 43, 1724–1734 (2016).
pubmed: 27422893
doi: 10.3899/jrheum.151376
Edwards, C. J. et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann. Rheum. Dis. 75, 1065–1073 (2016).
pubmed: 26792812
doi: 10.1136/annrheumdis-2015-207963
Mease, P. et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N. Engl. J. Med. 377, 1537–1550 (2017).
pubmed: 29045212
doi: 10.1056/NEJMoa1615975
Gladman, D. et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N. Engl. J. Med. 377, 1525–1536 (2017).
pubmed: 29045207
doi: 10.1056/NEJMoa1615977
Mease, P. et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann. Rheum. Dis. 79, 1400–1413 (2020).
pubmed: 32759265
doi: 10.1136/annrheumdis-2019-216761
Mease, P. J. et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann. Rheum. Dis. 80, 312–320 (2020).
doi: 10.1136/annrheumdis-2020-218870
Mease, P. et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. Lancet 392, 2367–2377 (2018).
doi: 10.1016/S0140-6736(18)32483-8
Papp, K. et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N. Engl. J. Med. 379, 1313–1321 (2018).
pubmed: 30205746
doi: 10.1056/NEJMoa1806382
Mease P. J., et al. Efficacy and safety of deucravacitinib (BMS-986165), an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: results from a phase 2, randomized, double-blind, placebo-controlled trial [abstract]. Arthritis Rheumatol. 72 (Suppl. 10), L03 (2020).
Coates, L. C. et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 68, 1060–1071 (2016).
Gossec, L. et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann. Rheum. Dis. 79, 700–712 (2020).
pubmed: 32434812
doi: 10.1136/annrheumdis-2020-217159
Singh, J. A. et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 71, 5–32 (2019).
pubmed: 30499246
doi: 10.1002/art.40726
Husted, J. A., Gladman, D. D., Farewell, V. T. & Cook, R. J. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum. 45, 151–158 (2001).
pubmed: 11324779
doi: 10.1002/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T
Moverley, A. R., Vinall-Collier, K. A. & Helliwell, P. S. It’s not just the joints, it’s the whole thing: qualitative analysis of patients’ experience of flare in psoriatic arthritis. Rheumatology 54, 1448–1453 (2015).
pubmed: 25752311
doi: 10.1093/rheumatology/kev009
Gossec, L. et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the psoriatic arthritis impact of disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann. Rheum. Dis. 73, 1012–1019 (2014).
pubmed: 24790067
doi: 10.1136/annrheumdis-2014-205207
Tillett, W. et al. A multicentre nominal group study to rank outcomes important to patients and their representation in existing composite outcome measures for psoriatic arthritis. J. Rheumatol. 44, 1445–1452 (2017).
pubmed: 28765241
doi: 10.3899/jrheum.161459
Geijer, M. et al. Health-related quality of life in early psoriatic arthritis compared with early rheumatoid arthritis and a general population. Semin. Arthritis Rheum. 51, 246–252 (2021).
pubmed: 33385865
doi: 10.1016/j.semarthrit.2020.10.010
Orbai, A.-M. et al. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann. Rheum. Dis. 76, 673–680 (2017).
pubmed: 27613807
doi: 10.1136/annrheumdis-2016-210242
Ware, J. E. Jr & Sherbourne, C. D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 30, 473–483 (1992).
pubmed: 1593914
doi: 10.1097/00005650-199206000-00002
Nord, E. EuroQol: health-related quality of life measurement. Valuations of health states by the general public in Norway. Health Policy 18, 25–36 (1991).
pubmed: 10112299
doi: 10.1016/0168-8510(91)90141-J
McKenna, S. P. et al. Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis. Ann. Rheum. Dis. 63, 162–169 (2004).
pubmed: 14722205
pmcid: 1754880
doi: 10.1136/ard.2003.006296
Holland, R. et al. Psoriatic arthritis impact of disease (PsAID12) was provisionally endorsed at Omeract 2018 as core instrument to measure psoriatic arthritis-specific health-related quality of life in randomized controlled trials and longitudinal observational studies. J. Rheumatol. 46, 990–995 (2019).
pubmed: 30554154
doi: 10.3899/jrheum.181077
Coates, L. C. et al. Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire. Health Qual. Life Outcomes 18, 173 (2020).
pubmed: 32513190
pmcid: 7282161
doi: 10.1186/s12955-020-01422-z
Tillett, W. et al. Disease characteristics and the burden of joint and skin involvement amongst people with psoriatic arthritis: a population survey. Rheumatol. Ther. 7, 617–637 (2020).
pubmed: 32700230
pmcid: 7410983
doi: 10.1007/s40744-020-00221-8
Kavanaugh, A. et al. The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. Ann. Rheum. Dis. 78, 1215–1219 (2019).
pubmed: 31113794
doi: 10.1136/annrheumdis-2018-215003
McHugh, N. et al. Evaluation of the economic burden of psoriatic arthritis and the relationship between functional status and healthcare costs. J. Rheumatol. 47, 701–707 (2020).
pubmed: 31416922
doi: 10.3899/jrheum.190083
Thomsen, S. F., Skov, L., Dodge, R., Hedegaard, M. S. & Kjellberg, J. Socioeconomic costs and health inequalities from psoriasis: a cohort study. Dermatology 235, 372–379 (2019).
pubmed: 31238322
doi: 10.1159/000499924
Husni, M. E., Merola, J. F. & Davin, S. The psychosocial burden of psoriatic arthritis. Semin. Arthritis Rheum. 47, 351–360 (2017).
pubmed: 28802776
doi: 10.1016/j.semarthrit.2017.05.010
Tillett, W. et al. Factors influencing work disability in psoriatic arthritis: first results from a large UK multicentre study. Rheumatology 54, 157–162 (2015).
pubmed: 25125591
doi: 10.1093/rheumatology/keu264
Tillett, W., de-Vries, C. & McHugh, N. J. Work disability in psoriatic arthritis: a systematic review. Rheumatology 46, 990–995 (2012).
Tillett, W. et al. Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug treatment on work disability and clinical outcome in a multicentre observational cohort study of psoriatic arthritis. Rheumatol 56, 603–612 (2017).
Kristensen, L. E. et al. Societal costs and patients’ experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study. Ann. Rheum. Dis. 76, 1495–1501 (2017).
pubmed: 28137915
doi: 10.1136/annrheumdis-2016-210579
Conaghan, P. G. et al. Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world study. RMD Open 6, e001240 (2020).
pubmed: 32611650
pmcid: 7425192
doi: 10.1136/rmdopen-2020-001240
Walsh, J. A. et al. Work productivity loss and fatigue in psoriatic arthritis. J. Rheumatol. 41, 1670–1674 (2014).
pubmed: 25028377
doi: 10.3899/jrheum.140259
Tan, J. S. Q., Fong, W., Kwan, Y. H. & Leung, Y. Y. Prevalence and variables associated with fatigue in psoriatic arthritis: a cross-sectional study. Rheumatol. Int. 40, 1825–1834 (2020).
pubmed: 32776160
doi: 10.1007/s00296-020-04678-2
Zhao, S. S. et al. Systematic review of mental health comorbidities in psoriatic arthritis. Clin. Rheumatol. 39, 217–225 (2020).
pubmed: 31486931
doi: 10.1007/s10067-019-04734-8
Visalli, E., Crispino, N. & Foti, R. Multidisciplinary management of psoriatic arthritis: the benefits of a comprehensive approach. Adv. Ther. 36, 806–816 (2019).
pubmed: 30805821
doi: 10.1007/s12325-019-00901-0
Cobo-Ibanez, T. et al. Multidisciplinary dermatology-rheumatology management for patients with moderate-to-severe psoriasis and psoriatic arthritis: a systematic review. Rheumatol. Int. 36, 221–229 (2016).
pubmed: 26438388
doi: 10.1007/s00296-015-3377-z
Soare, A. et al. Cutting edge: homeostasis of innate lymphoid cells is imbalanced in psoriatic arthritis. J. Immunol. 200, 1249–1254 (2018).
pubmed: 29330320
doi: 10.4049/jimmunol.1700596
Kaeley, G. S., Bakewell, C. & Deodhar, A. The importance of ultrasound in identifying and differentiating patients with early inflammatory arthritis: a narrative review. Arthritis Res. Ther. 22, 1 (2020).
pubmed: 31898524
pmcid: 6939339
doi: 10.1186/s13075-019-2050-4
Kampylafka, E. et al. Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation – data from the prospective IVEPSA study. Arthritis Res. Ther. 21, 178 (2019).
pubmed: 31349876
pmcid: 6659205
doi: 10.1186/s13075-019-1957-0
Feld, J. Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis? Rheumatology 59, 1340–1346 (2019).
doi: 10.1093/rheumatology/kez457
Ritchlin, C. & Scher, J. U. Strategies to improve outcomes in psoriatic arthritis. Curr. Rheumatol. Rep. 21, 72 (2019).
pubmed: 31813074
doi: 10.1007/s11926-019-0876-z
Moncada, R. et al. Integrating microarray-based spatial transcriptomics and single-cell RNA-seq reveals tissue architecture in pancreatic ductal adenocarcinomas. Nat. Biotechnol. 38, 333–342 (2020).
pubmed: 31932730
doi: 10.1038/s41587-019-0392-8
Mimitou, E. P. et al. Multiplexed detection of proteins, transcriptomes, clonotypes and CRISPR perturbations in single cells. Nat. Methods 16, 409–412 (2019).
pubmed: 31011186
pmcid: 6557128
doi: 10.1038/s41592-019-0392-0
Haberman, R. H., Castillo, R. & Scher, J. U. Induction of remission in biologic-naive, severe psoriasis and PsA with dual anti-cytokine combination. Rheumatology 60, e225–e226 (2021).
pubmed: 33369644
doi: 10.1093/rheumatology/keaa880
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03662542 (2021). A study of the efficacy and safety of combination therapy with guselkumab and golimumab in participants with moderately to severely active ulcerative colitis (VEGA).
Goldman, M. The innovative medicines initiative: a European response to the innovation challenge. Clin. Pharmacol. Ther. 91, 418–425 (2012).
pubmed: 22318619
doi: 10.1038/clpt.2011.321
Dolgin, E. Massive NIH–industry project opens portals to target validation. Nat. Rev. Drug Discov. 18, 240–242 (2019).